Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations

Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations has resulted in new specific treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldinger, Simone M., Murer, Carla, Stieger, Pascale, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041182/
https://www.ncbi.nlm.nih.gov/pubmed/26217117
http://dx.doi.org/10.1016/j.ejcsup.2013.07.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041182/
https://www.ncbi.nlm.nih.gov/pubmed/26217117
http://dx.doi.org/10.1016/j.ejcsup.2013.07.011

Ejemplares similares